Categoria: english

The Leading German Business Publication Handelsblatt did a profile on the German cannabis biotech company Avextra providing insights into botanical drug development Made in Germany.

Avextra and SynQube jointly announce their strategic partnership. Both partners are combining their extensive expertise in the field of cannabinoid therapy to improve patient care and fulfill the requirements for reimbursement.

Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce a joint study with the German Pain Association (DGS) focused on chemotherapy-induced neuropathic pain (CINP).

Lisbon, January 17th, 2024 – Avextra, the leading German manufacturer of cannabis-based medicines, has entered a strategic, long-term partnership with the Instituto Universitário de Ciências da Saúde-Cooperativa de Ensino Superior Politécnico e Universitário (IUCS-CESPU) focused on Research & Development (R&D) of regulator approved medicines based on the cannabis plant.

Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim of designing robust clinical trials for proprietary Cannabis-based medicines that can achieve regulatory approval.

Marla Luther is the new Chief Strategy Officer at Eurox Pharma, the leading European vertically-integrated manufacturer of cannabis-based medicines, which will operate under the Avextra name.